HPMA copolymer–aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines
- 1 September 2005
- journal article
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 13 (8-9) , 459-470
Abstract
N-(2-Hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin (Dox) has already shown clinical activity in breast cancer patients. Moreover, we have recently found that an HPMA conjugate containing a combination of both Dox and the aromatase inhibitor aminoglutethimide (AGM) shows significantly increased anti-tumour activity in vitro. To better understand the mechanism of action of HPMA copolymer-AGM conjugates several models were used here to investigate their effect on cell growth and aromatase inhibition. Cytotoxicity of HPMA copolymer conjugates containing AGM, Dox and also the combination AGM-Dox was determined by MTT assay in MCF-7 and MCF-7ca cells. Androstenedione (5 x 10(- 8) M) stimulates the growth of MCF-7ca cells. Both free AGM and polymer-bound AGM (0.2-0.4 mg/ml) were shown to block this mitogenic activity. When MCF-7ca cells were incubated [(3)H]androstenedione both AGM and HPMA copolymer-GFLG-AGM (0.2 mg/ml AGM-equiv.) showed the ability to inhibit aromatase. Although, free AGM was able to inhibit isolated human placental microsomal aromatase in a concentration dependent manner, polymer-bound AGM was not, suggesting that drug release is essential for activity of the conjugate. HPMA copolymer conjugates containing aromatase inhibitors have potential for the treatment of hormone-dependant cancers, and it would be particularly interesting to explore further as potential therapies in post-menopausal women as components of combination therapy.Keywords
This publication has 23 references indexed in Scilit:
- Polymer Therapeutics Designed for a Combination Therapy of Hormone‐Dependent CancerAngewandte Chemie International Edition, 2005
- N-(2-Hydroxypropyl) methacrylamide Copolymer Conjugates2005
- A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid TumorsClinical Cancer Research, 2004
- AP-5346Drugs of the Future, 2004
- Aromatase inhibitors for breast cancer: lessons from the laboratoryNature Reviews Cancer, 2003
- The dawning era of polymer therapeuticsNature Reviews Drug Discovery, 2003
- Tamoxifen: a most unlikely pioneering medicineNature Reviews Drug Discovery, 2003
- Tamoxifen Resistant and Refractory Breast CancerDrugs, 2002
- Effect of androstenedione on growth of untransfected and aromatase-transfected MCF-7 cells in cultureThe Journal of Steroid Biochemistry and Molecular Biology, 1993
- Preclinical evaluation of polymer-bound doxorubicinJournal of Controlled Release, 1992